CytoDyn Inc. (CYDY) - Investor Relations <alerts@em.equisolve.com>
8:03 AM (41 minutes ago)
to me

CytoDyn Inc.
CytoDyn Inc. has just released the following news:

NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
Click here to read the full article

If you have any questions, or would like to contact Investor Relations, please reply to this email.

CytoDyn Inc.
1111 Main Street, Suite 660, Vancouver, WA 98660 United States of America
https://www.cytodyn.com